SLC9A3R1 Genotype

If you have had a kidney stone, broken a bone in an unusual place, or watched a close relative deal with either, you may have wondered whether something in your DNA is working against you. SLC9A3R1 (sodium-hydrogen exchanger regulatory factor 1) is one of the genes researchers point to when this question comes up, although the strength of the link is still being worked out.

This test reads the version of SLC9A3R1 you were born with. The answer does not change. What it gives you is a one-time piece of inherited information that can add context to how you and your clinician decide to monitor your kidneys, your bones, and your minerals over time.

What This Gene Actually Does

SLC9A3R1 produces a protein called NHERF1, sometimes labeled EBP50. NHERF1 acts as a kind of organizer inside cells. It holds ion transporters, receptors, and structural proteins in their proper places along cell membranes in many tissues that line internal surfaces, including the kidneys, gut, and skin. Without functioning NHERF1, the machinery that moves phosphate and other minerals in and out of cells loses some of its precision.

In a large study of more than 10,000 people, those born without a working copy of SLC9A3R1 showed shifts in the chemical signals that regulate calcium and phosphate. That observation in humans is what anchors the gene to mineral metabolism, and it is what links it to the kidney stone and bone findings that follow.

Kidney Stone Risk

Variants in SLC9A3R1 have been identified as a monogenic cause of early-onset kidney stones and calcium deposits in the kidneys (nephrocalcinosis) in some families. When researchers performed whole exome sequencing in 51 families with early-onset stones, SLC9A3R1 was among the genes that explained certain cases. In adult stone-formers, the picture is more nuanced and remains debated.

A study of 787 adult kidney stone formers found that rare variants in genes linked to nephrolithiasis, including SLC9A3R1, were among the most frequently detected. A separate analysis of 901 adult stone patients found that carriers of rare variants in stone-disease genes collectively had higher stone recurrence over a three-year follow-up. Importantly, that same study reported that monoallelic likely pathogenic or pathogenic variants in SLC9A3R1 specifically did not produce the expected biochemical changes, and the authors suggested this calls into question SLC9A3R1's role as a strong risk factor for stone disease in adults. The biochemistry in carriers is often subtle, meaning a standard urine and blood mineral panel may look unremarkable.

What this means for you: if you have already had stones, especially before age 25 or repeatedly, a positive SLC9A3R1 result is one piece of context that may help your clinician decide on the intensity of imaging and 24-hour urine chemistries. It is not a standalone explanation for recurrent stones, and the evidence for monoallelic adult carriers is still evolving.

Atypical Femur Fractures

An atypical femur fracture is a break in the thigh bone that happens with little or no trauma. It is the kind of fracture people associate with long-term bisphosphonate use, but inherited bone fragility may also play a role. In a study of 25 patients with atypical femur fractures, heterozygous rare variants in SLC9A3R1 (and the related SLC34A1 gene) showed up at a notably high frequency, leading the authors to propose them as a possible genetic risk factor connected to a phosphate-handling disorder called NPHLOP2.

A larger subsequent whole exome sequencing study of 139 atypical femur fracture patients did not replicate the SLC34A1 or SLC9A3R1 association and pointed instead to other candidate genes. The investigators noted that the genetics of atypical femur fractures are not widely shared across patients. So while the original finding is interesting, the link between SLC9A3R1 and atypical femur fractures should be treated as unsettled. If you have ever had an unexplained low-impact femur fracture, or if you take long-term medication that affects bone turnover, knowing your SLC9A3R1 status is one input into how your bone density and phosphate levels are tracked, not a definitive answer.

Psoriasis Susceptibility

A different mechanism connects this gene to psoriasis. On chromosome 17q25, a small DNA change sits between SLC9A3R1 and a neighboring gene called NAT9. That change wipes out a binding site for a regulatory protein called RUNX1, which normally controls how strongly nearby genes are switched on. The variant was originally linked to psoriasis susceptibility in an association study, with SLC9A3R1 expression highest in the upper layers of skin and in resting T cells. However, a later well-powered study of more than 500 pedigrees did not replicate the association, so the link remains debated.

Even if real, this particular variant would be only one of many genetic factors contributing to psoriasis risk and does not predict whether you will develop the disease on its own. It is most useful as context if you already have a family history of psoriasis or autoimmune skin conditions.

Breast Cancer Prognosis

In a study of 222 women with invasive breast cancer, the location of NHERF1 protein inside tumor cells carried prognostic information. Tumors with NHERF1 sitting in the nucleus tended to be smaller and estrogen receptor positive. Loss of nuclear NHERF1 was independently linked to worse disease-free survival. The combination of nuclear NHERF1 loss with estrogen receptor negativity marked particularly aggressive disease.

This is tumor-level evidence, not germline genotype evidence. A SLC9A3R1 genotype test on a buccal swab does not predict breast cancer risk or prognosis. If you have been diagnosed with breast cancer and want this information, it has to come from tumor immunohistochemistry, not from this assay.

Mineral Metabolism in Apparently Healthy People

Beyond defined diseases, SLC9A3R1 sits in the middle of how your body regulates phosphate. In the human knockout study of over 10,000 individuals, those without a functioning copy of this gene showed measurable changes in calcium and phosphate signaling chemistry. This suggests that even people who have not yet had a kidney stone or fracture may carry a quieter shift in mineral handling that could matter over decades.

This evidence comes from broad biochemical screening, not from outcome trials, and you should not assume that a positive SLC9A3R1 result will translate to a specific disease. It does, however, give you a reason to pay closer attention to your phosphate, calcium, vitamin D, and kidney function over time.

Why This Is a One-Time Test

Your SLC9A3R1 genotype is fixed at conception. The result will not change next year, next decade, or after any intervention. You do not need to repeat the test unless your lab uses a different method to confirm an unexpected finding, or unless a confirmatory technique like Sanger sequencing is recommended after a chip-based call.

The value of this result is not in tracking a number over time. It is in using the answer to add context to ongoing decisions: how often you image for kidney stones, how aggressively you screen bone density, when you order 24-hour urine chemistries, and how seriously you take phosphate handling. The companion phenotype tests are the ones that need to move with you. Serum calcium, phosphate, 25-hydroxyvitamin D, intact PTH, and kidney function are reasonable to track at least yearly if you carry a risk variant. A 24-hour urine for calcium and phosphate, plus periodic kidney imaging, makes sense if you have had stones.

When Results Can Be Misleading

• Variant panel coverage: the assay only detects the specific changes it is designed to find. A negative result does not rule out other rare changes in the same gene that the panel does not cover.
• Ancestry effects: allele frequencies for SLC9A3R1 variants differ by ancestral background. A variant that is well studied in one population may have unknown clinical meaning in another.
• Variants of uncertain significance: the lab may report a change in the gene that has not yet been linked to disease. This is not a positive or negative result. It is an open question that may take years of further research to settle.
• Unsettled clinical associations: the link between SLC9A3R1 variants and adult kidney stones, atypical femur fractures, and psoriasis has not been consistently replicated. A positive result is information, not a diagnosis.
• Direct-to-consumer comparisons: if you have seen a 23andMe-style report covering nearby DNA, that is not the same as a clinical-grade SLC9A3R1 genotype. Consumer panels rarely interrogate the specific rare variants studied in research settings here.

What an Out-of-Pattern Result Should Prompt

If your result identifies a known pathogenic or likely pathogenic variant, the first step is confirmation by a different method when the original platform is chip-based. The second step is to order companion phenotype tests if you have not already. Serum calcium, phosphate, 25-hydroxyvitamin D, intact parathyroid hormone (PTH), creatinine, cystatin C, and an estimated kidney filtration rate (eGFR) form the basic mineral and kidney picture. A 24-hour urine collection for calcium, phosphate, and creatinine adds the next layer.

If you have a stone history, a kidney ultrasound or low-dose CT is reasonable to look for stones you do not yet know about. If you have a fracture history, a DEXA scan of your spine and hips, alongside bone turnover markers, helps clarify whether your bone biology is part of the picture. A referral to a nephrologist, endocrinologist, or genetic counselor is appropriate when results meaningfully change your monitoring plan or when family members may need testing too.

What This Means for Your Family

Genetic variants in SLC9A3R1 are inherited. If you carry one, each of your biological children, full siblings, and parents has roughly a one in two chance of carrying the same variant. This does not mean any of them will develop kidney stones, fractures, or psoriasis. Carrying a risk variant may raise the odds but does not guarantee the outcome, which is what scientists mean by incomplete penetrance: the variant is present, but the disease may never appear. It does mean that a family member who has had unexplained stones, fractures, or mineral abnormalities now has a concrete reason to consider their own testing.